Ozvegy-Laczka C - Search Results

1

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.

Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B. Hegedüs C, et al. Biochem Pharmacol. 2012 Aug 1;84(3):260-7. doi: 10.1016/j.bcp.2012.04.010. Epub 2012 Apr 21. Biochem Pharmacol. 2012. PMID: 22548830

2

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

Ozvegy-Laczka C, Hegedus T, Várady G, Ujhelly O, Schuetz JD, Váradi A, Kéri G, Orfi L, Német K, Sarkadi B. Ozvegy-Laczka C, et al. Mol Pharmacol. 2004 Jun;65(6):1485-95. doi: 10.1124/mol.65.6.1485. Mol Pharmacol. 2004. PMID: 15155841

3

ABCG2 -- a transporter for all seasons.

Sarkadi B, Ozvegy-Laczka C, Német K, Váradi A. Sarkadi B, et al. FEBS Lett. 2004 Jun 1;567(1):116-20. doi: 10.1016/j.febslet.2004.03.123. FEBS Lett. 2004. PMID: 15165903 Free article. Review.

4

Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization.

Cserepes J, Szentpétery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Váradi A, Sarkadi B, Elkind NB. Cserepes J, et al. Biochem Biophys Res Commun. 2004 Jul 30;320(3):860-7. doi: 10.1016/j.bbrc.2004.06.037. Biochem Biophys Res Commun. 2004. PMID: 15240127

5

Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

Ozvegy-Laczka C, Várady G, Köblös G, Ujhelly O, Cervenak J, Schuetz JD, Sorrentino BP, Koomen GJ, Váradi A, Német K, Sarkadi B. Ozvegy-Laczka C, et al. J Biol Chem. 2005 Feb 11;280(6):4219-27. doi: 10.1074/jbc.M411338200. Epub 2004 Nov 22. J Biol Chem. 2005. PMID: 15557326 Free article.

6

Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.

Ozvegy-Laczka C, Köblös G, Sarkadi B, Váradi A. Ozvegy-Laczka C, et al. Biochim Biophys Acta. 2005 Feb 1;1668(1):53-63. doi: 10.1016/j.bbamem.2004.11.005. Biochim Biophys Acta. 2005. PMID: 15670731 Free article.

7

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O, Szabó K, Homolya L, Váradi A, Buday L, Kéri G, Német K, Sarkadi B. Elkind NB, et al. Cancer Res. 2005 Mar 1;65(5):1770-7. doi: 10.1158/0008-5472.CAN-04-3303. Cancer Res. 2005. PMID: 15753373

8

Single nucleotide polymorphisms modify the transporter activity of ABCG2.

Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE. Morisaki K, et al. Cancer Chemother Pharmacol. 2005 Aug;56(2):161-72. doi: 10.1007/s00280-004-0931-x. Epub 2005 Apr 19. Cancer Chemother Pharmacol. 2005. PMID: 15838659

9

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.

Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Ozvegy-Laczka C, et al. Drug Resist Updat. 2005 Feb-Apr;8(1-2):15-26. doi: 10.1016/j.drup.2005.02.002. Drug Resist Updat. 2005. PMID: 15939339 Review.

10

The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.

Cervenak J, Andrikovics H, Ozvegy-Laczka C, Tordai A, Német K, Váradi A, Sarkadi B. Cervenak J, et al. Cancer Lett. 2006 Mar 8;234(1):62-72. doi: 10.1016/j.canlet.2005.01.061. Epub 2005 Dec 7. Cancer Lett. 2006. PMID: 16337740 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page